Details of the Drug Reposition

General Information of This Drug (ID: DMF8DNE)

Drug Name
Framycetin   DMF8DNE
Synonyms
Neomycin; neomycin; NEOMYCIN B; Soframycin; Actiline; Mycifradin; Fradiomycin; Soframycine; Framycetinum; Framycetine; Framicetina; Neomas; Fradiomycinum; Antibiotique; Nivemycin; Actilin; Neolate; Enterfram; Myacyne; Framygen; Caswell No 595; Vonamycin powder V; Neomycin B sulfate; Neomin; Neomcin; Fradiomycin B; Neo-Rx; Neomicina [DCIT]; Framycetinum [INN-Latin]; PIMAVECORT; Neobrettin; Neo-Fradin; 119-04-0; Neomycine [INN-French]; Neomycinum [INN-Latin]; Framycetine [INN-French]; Framicetina [INN-Spanish]; USAF CB-19; Endomixin; Fraquinol; Myacine; Myciguent; NMY; Neobiotic; Neomicina; Neomycinum; Tuttomycin; VONAMYCIN; NEOMYCIN AND POLYMYXIN B SULFATES; NEOMYCIN SULFATE; Neomycin solution; Soframycin Ophthalmic; Antibiotic 10676; Antibiotic produced by Streptomyces decaris Neomycin B; Framycetin (INN); Soframycin (TN); Framycetin [INN:BAN:DCF]; Sofra-Tulle (TN); BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG; BDG-(1-4)NEB-(5-1)RIB-(3-1)NED; (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside; (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol; D-Streptamine, O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-O-beta-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-alpha-D-glucopyranosyl-(1->4)]-2-deoxy
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
9 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Keratitis DISMFOEI N.A. Approved [1]
Hepatic coma DISILSPO N.A. Approved [2]
Blepharoconjunctivitis DIS4PG4J N.A. Approved [2]
Bacterial infection DIS5QJ9S 1A00-1C4Z Approved [3]
Hepatic encephalopathy DISEAKAN DB99.5 Approved [2]
Acute liver failure DIS5EZKX DB91 Approved [4]
Alcoholic cirrhosis of liver DISQ1WRT DB94 Approved [4]
Urinary tract infection DISMT6UV GC08 Approved [5]
Corneal abrasion DIS3SD7J NA06.4 Approved [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Indications(s)
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Otitis externa DISYCORK AA00-AA13 Discontinued in Phase 2 [6]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Uveitis DISV0RYS 9A96.Z Investigative [2]
------------------------------------------------------------------------------------

References

1 Bacterial isolates, antimicrobial susceptibility, and clinical characteristics of bacterial keratitis in dogs presenting to referral practice in Australia. Vet Ophthalmol. 2016 Sep;19(5):418-26.
2 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3 Drug information of Framycetin, 2008. eduDrugs.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 709).
5 Prostatectomy and infection. J Urol. 1971 Dec;106(6):910-2.
6 Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia